OpGen
Latest round
- Series C
Last raised
- Mar 2012
Total raised
- $28M
Investors
- 8
About OpGen
OpGen, Inc.Founded in 2002 and headquartered in Rockville, US, OpGen, Inc. specializes in molecular diagnostics aimed at optimizing treatment for drug-resistant infections.99 mn in May 2015. The company's operations have remained consistent since its founding, with no significant pivots mentioned.OpGen develops advanced molecular diagnostic solutions focused on optimizing treatment for life-threatening, drug-resistant infections. Their flagship products include multiplexed syndromic molecular panels for swift and accurate pathogen detection, directly addressing antimicrobial resistance (AMR).OpGen is focused on developing and launching new molecular diagnostic products to enhance its offerings against drug-resistant infections. The company aims to expand its market reach into additional geographic regions, particularly across Europe and emerging markets, by 2025.
Who invested in OpGen
8 investors across 3 rounds
See all investors in OpGen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about OpGen
Who invested in OpGen?
OpGen has 8 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has OpGen raised?
OpGen has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did OpGen last raise money?
OpGen's most recent round on record is a Series C, in Mar 2012.
What does OpGen do?
OpGen is a biotechnology company.
Where is OpGen headquartered?
OpGen is headquartered in Rockville, US.
Which VCs invest in companies like OpGen?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at OpGen's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like OpGen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.